AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29641671 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl
Number of subjects: 60
Study 29641671 — intervention group
Group type: COMPARATOR
Intervention: Control group with tramadol hydrochloride injection
Number of subjects: 60
Study 26769742 — intervention group
Group type: COMPARATOR
Intervention: Information-only SMS text messages
Number of subjects: 1372
Study 26769742 — intervention group
Group type: COMPARATOR
Intervention: Interactive SMS text messages
Number of subjects: 1372
Study 26769742 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 1372
Study 25605477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 218
Study 25605477 — intervention group
Group type: COMPARATOR
Intervention: Dispersible artemether-lumefantrine (AL)
Number of subjects: 218
Study 24221391 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 0
Study 24221391 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 0
Study 24221391 — intervention group
Group type: COMPARATOR
Intervention: TAVR
Number of subjects: 0
Study 24221391 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 0
Study 21178977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (12-month regimen)
Number of subjects: 138
Study 21178977 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil and oral dexamethasone (12-month regimen)
Number of subjects: 138
Study 21178977 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measurement
Number of subjects: 138
Study 18694917 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-bridging external fixation with alternating electric current stimulation (EF + ES)
Number of subjects: 2
Study 18694917 — intervention group
Group type: COMPARATOR
Intervention: Wrist-bridging external fixation without alternating electric current stimulation (EF)
Number of subjects: 2
Study 16569807 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil sustained-release (SR) hypertension treatment
Number of subjects: 1152
Study 16569807 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based hypertension treatment
Number of subjects: 1152
Study 12818266 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily for up to 12 months
Number of subjects: 1326
Study 12818266 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40, 20, or 10 mg daily for up to 6 months
Number of subjects: 1326
Study 12818266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1326
Study 10393140 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized triacylglycerol formula
Number of subjects: 0
Study 10393140 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard formula
Number of subjects: 0
Study 10393140 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 0
Study 8992517 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol (exact dosage and duration not specified)
Number of subjects: 62
Study 1854052 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene catheter (Leader Cath. 115‐09)
Number of subjects: 101
Study 1854052 — intervention group
Group type: COMPARATOR
Intervention: Teflon catheter (Plastimed Seldicath)
Number of subjects: 101
Study 6362698 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam (0.25 mg)
Number of subjects: 0
Study 6362698 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2.0 mg)
Number of subjects: 0
Study 30804065 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted serum magnesium concentrations (increase of 0.1 mmol/L)
Number of subjects: 404847
Study 30804065 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted serum calcium concentrations (increase of 0.5 mg/dL)
Number of subjects: 404847
Study 28406384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (D2 dopamine agonist)
Number of subjects: 13
Study 28406384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27030543 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly-Pro-Ile-Gly-Ser (GPIGS) penta-peptide
Number of subjects: 22
Study 25009138 — intervention group
Group type: EXPERIMENTAL
Intervention: New-look EpiPen
Number of subjects: 271
Study 25009138 — intervention group
Group type: COMPARATOR
Intervention: Original EpiPen
Number of subjects: 271
Study 25009138 — intervention group
Group type: COMPARATOR
Intervention: Anapen
Number of subjects: 271
Study 25009138 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 271
Study 23177300 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent implantation
Number of subjects: 30
Study 20926970 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled and held in an upright position during heel lance (experimental group)
Number of subjects: 42
Study 20926970 — intervention group
Group type: COMPARATOR
Intervention: Standard care position (control group)
Number of subjects: 42
Study 20926970 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled (experimental group)
Number of subjects: 42
Study 18591543 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy for 90 days, consisting of 14-day cycles followed by 3-day higher doses.
Number of subjects: 254
Study 18591543 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 254
Study 15842212 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/die)
Number of subjects: 90
Study 15842212 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (17-beta-estradiol 1 mg plus norethisterone acetate 0.5 mg)
Number of subjects: 90
Study 15842212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12433766 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured screening test
Number of subjects: 582
Study 12433766 — intervention group
Group type: COMPARATOR
Intervention: Parent led method
Number of subjects: 582
Study 9843011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 46
Study 9843011 — intervention group
Group type: COMPARATOR
Intervention: Systemic tetracycline
Number of subjects: 46
Study 9843011 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' global assessment
Number of subjects: 46
Study 9843011 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between assessments
Number of subjects: 46
Study 9843011 — intervention group
Group type: EXPERIMENTAL
Intervention: Soreness
Number of subjects: 46
Study 7640501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungus Lipid‐reducing Capsule (FLC) treated group
Number of subjects: 230
Study 7640501 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study 7640501 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented treated group
Number of subjects: 230
Study 2569191 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg in soft gelatine capsule
Number of subjects: 12
Study 2569191 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg in uncoated tablet
Number of subjects: 12
Study 2569191 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12
Study 786682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythritol trinitrate (PETRIN)
Number of subjects: 12
Study 786682 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 12
Study 786682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28755481 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilization group (n = 45)
Number of subjects: 119
Study 28755481 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour bed rest group (n = 40)
Number of subjects: 119
Study 28755481 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour bed rest group (n = 34)
Number of subjects: 119
Study 26879051 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person CBT for ten weeks
Number of subjects: 230
Study 26879051 — intervention group
Group type: COMPARATOR
Intervention: IVR-based CBT for ten weeks
Number of subjects: 230
Study 24721597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral closing wedge technique
Number of subjects: 110
Study 24721597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined wedge osteotomy technique
Number of subjects: 110
Study 23893227 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal sexuality education program (Experimental group)
Number of subjects: 55
Study 23893227 — intervention group
Group type: COMPARATOR
Intervention: Control group (received program after the experiment)
Number of subjects: 55
Study 20637332 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap procedure
Number of subjects: 260
Study 20637332 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 260
Study 20637332 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap
Number of subjects: 260
Study 18400704 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain diet
Number of subjects: 30
Study 18400704 — intervention group
Group type: COMPARATOR
Intervention: Refined-cereal-grain diet
Number of subjects: 30
Study 16783046 — intervention group
Group type: EXPERIMENTAL
Intervention: Praneem polyherbal vaginal tablet used intravaginally once daily for 14 consecutive days
Number of subjects: 20
Study 16783046 — intervention group
Group type: EXPERIMENTAL
Intervention: Praneem polyherbal vaginal tablet
Number of subjects: 20
Study 14512000 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg daily)
Number of subjects: 87
Study 14512000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 11716075 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide/methylcellulose paste (group A)
Number of subjects: 15
Study 11716075 — intervention group
Group type: EXPERIMENTAL
Intervention: Camphorated parachlorophenol/calcium hydroxide paste (group B)
Number of subjects: 15
Study 11716075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine/methylcellulose gel (group C)
Number of subjects: 15
Study 11716075 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide points (group D)
Number of subjects: 15
Study 11716075 — intervention group
Group type: COMPARATOR
Intervention: Positive control (no medication)
Number of subjects: 15
Study 9384018 — intervention group
Group type: EXPERIMENTAL
Intervention: Victorian Order of Nurses (VON) services in the home
Number of subjects: 163
Study 7942832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume digital subtraction renal angiography with low osmolar contrast media
Number of subjects: 0
Study 7942832 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic renal angiography and angioplasty
Number of subjects: 0
Study 3149082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 9
Study 3149082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 9
Study 3149082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2291751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium naproxen 550 mg every 12 h
Number of subjects: 100
Study 2291751 — intervention group
Group type: COMPARATOR
Intervention: Sodium diclofenac 100 mg every 12 h
Number of subjects: 100
Study 1256106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner care
Number of subjects: 0
Study 1256106 — intervention group
Group type: COMPARATOR
Intervention: Regular clinic (control)
Number of subjects: 0
Study 31101682 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine
Number of subjects: 24
Study 31101682 — intervention group
Group type: COMPARATOR
Intervention: best standard therapy (BST)
Number of subjects: 24
Study 28383414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5% lidocaine and 25 mg/g prilocaine, 5g applied preoperatively)
Number of subjects: 146
Study 28383414 — intervention group
Group type: COMPARATOR
Intervention: Control group (lidocaine gel used for lubrication of urinary catheter)
Number of subjects: 146
Study 26129630 — intervention group
Group type: EXPERIMENTAL
Intervention: 5AsT intervention tools
Number of subjects: 29
Study 23590257 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented intervention focused on timing and coordination of gait (TC)
Number of subjects: 44
Study 23590257 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gait intervention focusing on walking, endurance, balance, and strength (WEBS)
Number of subjects: 44
Study 21481862 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscopic imaging (MEI)
Number of subjects: 810
Study 21481862 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy with on-demand fluoroscopy
Number of subjects: 810
Study 19056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone recall system managed by pediatricians not previously involved in care (group 1)
Number of subjects: 285
Study 19056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone recall system managed by pediatricians from asthma clinic (group 2)
Number of subjects: 285
Study 19056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone recall system managed by pediatricians from asthma clinic with vaccine administered in the same clinic (group 3)
Number of subjects: 285
Study 17197590 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding educational material and individual coaching from a lactation counselor
Number of subjects: 401
Study 17197590 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding educational material with no counseling
Number of subjects: 401
Study 17197590 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care only
Number of subjects: 401
Study 15077287 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus MTX
Number of subjects: 428
Study 15077287 — intervention group
Group type: COMPARATOR
Intervention: MTX-only
Number of subjects: 428
Study 11408210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 5 mg/kg daily
Number of subjects: 65
Study 11408210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 5 mg/kg daily and rifampin (RIF) 10 mg/kg daily
Number of subjects: 65
Study 11408210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 5 mg/kg daily plus 10 mg of rifalazil once weekly
Number of subjects: 65
Study 11408210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 5 mg/kg daily and 25 mg of rifalazil once weekly
Number of subjects: 65
Study 11408210 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study 9495409 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine plus 75 mg i.m. diclofenac every 8 h
Number of subjects: 120
Study 9495409 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg intrathecal morphine plus 75 mg i.m. diclofenac every 8 h
Number of subjects: 120
Study 9495409 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg intrathecal morphine plus 75 mg i.m. diclofenac every 8 h
Number of subjects: 120
Study 9495409 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg intrathecal morphine plus i.m. diclofenac on demand
Number of subjects: 120
Study 9495409 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg intrathecal morphine plus i.m. diclofenac on demand
Number of subjects: 120
Study 9495409 — intervention group
Group type: COMPARATOR
Intervention: 0.025 mg intrathecal morphine plus i.m. diclofenac on demand
Number of subjects: 120
Study 7850234 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 7850234 — intervention group
Group type: COMPARATOR
Intervention: No haloperidol
Number of subjects: 0
Study 3053587 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate feeding (1 g/kg at 10 min, then 0.6 g/kg every 30 min)
Number of subjects: 7
Study 3053587 — intervention group
Group type: COMPARATOR
Intervention: Sweet placebo
Number of subjects: 7
Study 3053587 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate feeding
Number of subjects: 7
Study 31902925 — intervention group
Group type: EXPERIMENTAL
Intervention: DT algorithm for initial dose settings of VCM
Number of subjects: 654
Study 31902925 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose-setting methods
Number of subjects: 654
Study 30981162 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 120
Study 28287490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12-containing multiple micronutrient supplement
Number of subjects: 193
Study 28287490 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented
Number of subjects: 193
Study 25763531 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 to 1800 IU per day)
Number of subjects: 961
Study 25763531 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 961
Study 23484542 — intervention group
Group type: EXPERIMENTAL
Intervention: Curd consumption
Number of subjects: 40
Study 23484542 — intervention group
Group type: COMPARATOR
Intervention: Non-consuming curd
Number of subjects: 40
Study 21984924 — intervention group
Group type: EXPERIMENTAL
Intervention: gp140 vaccine (100 µg in 3 ml of Carbopol 974P based gel)
Number of subjects: 22
Study 21984924 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution in Carbopol gel
Number of subjects: 22
Study 18224343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine combination therapy
Number of subjects: 23
Study 16388436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction (Group A) - self-determined weight loss of approximately 5% body weight, energy restriction of -4 MJ per day.
Number of subjects: 20
Study 16388436 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B) - maintained body weight during the week before the competition.
Number of subjects: 20
Study 14633536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg metoclopramide
Number of subjects: 47
Study 14633536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg droperidol
Number of subjects: 47
Study 14633536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.13 mg/kg ondansetron
Number of subjects: 47
Study 14633536 — intervention group
Group type: COMPARATOR
Intervention: 10 mL saline
Number of subjects: 47
Study 14633536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg metoclopramide
Number of subjects: 47
Study 10717501 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 16
Study 10717501 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 16
Study 8955972 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg-1 and dexamethasone 4 mg (Group D)
Number of subjects: 60
Study 8955972 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 40 micrograms.kg-1 and saline (Group S)
Number of subjects: 60
Study 1485367 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 or 600 mg of racemic ibuprofen (chronic dosing)
Number of subjects: 45
Study 1485367 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 or 600 mg of racemic ibuprofen (single doses)
Number of subjects: 45
Study 1485367 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic dosing of ibuprofen
Number of subjects: 45
Study 3881033 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.25%
Number of subjects: 50
Study 3881033 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.125%
Number of subjects: 50
Study 3881033 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol (overall)
Number of subjects: 50
Study 3881033 — intervention group
Group type: COMPARATOR
Intervention: Timolol (overall)
Number of subjects: 50
Study 3881033 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol and Timolol (both groups)
Number of subjects: 50
Study 30600804 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise stimulus on the fracture site with intensities of 0.1‐0.6 N and frequencies of 0.1‐50 Hz
Number of subjects: 12
Study 30600804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no noise stimulus)
Number of subjects: 12
Study 30600804 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 12
Study 30113180 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Outcome Monitoring (ROM)
Number of subjects: 170
Study 30113180 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 170
Study 27459418 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional foot orthoses (FFO)
Number of subjects: 33
Study 27459418 — intervention group
Group type: COMPARATOR
Intervention: Sham orthosis
Number of subjects: 33
Study 24710254 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic thyroidectomy (ET) via anterior chest wall approach (group A)
Number of subjects: 320
Study 24710254 — intervention group
Group type: COMPARATOR
Intervention: Traditional open surgery (group B)
Number of subjects: 320
Study 23474349 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg Hyoscine N-butylbromide (HBB)
Number of subjects: 402
Study 23474349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 20461028 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg once daily for the first 7 weeks, increased to 120 mg for those with <30% pain reduction at week 7)
Number of subjects: 0
Study 20461028 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 20461028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18725858 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis
Number of subjects: 240
Study 18725858 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (intravenous corticosteroids or hemodilution)
Number of subjects: 240
Study 15993254 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention of CBT and pharmacology
Number of subjects: 232
Study 15993254 — intervention group
Group type: COMPARATOR
Intervention: Control group (less burden of chronic medical illness)
Number of subjects: 232